Infants are likely to avoid hospitalization thanks to a dose of nirsevimab during their first RSV season, a new study reports. The newly approved drug can help young children stay protected from the highly contagious respiratory illness that hospitalizes between 58,000 and 80,000 children under the age of 5 in the United States each year.
Nirsevimab is a monoclonal antibody that neutralizes respiratory syncytial virus (RSV). During 2022 and 2023, when RSV was spreading rampantly throughout communities, the European Union, United Kingdom, Canada, and the U.S. all approved the use of nirsevimab in neonates and infants during their first RSV season.
